In that scenario, Pfizer's COVID vaccine was a goldmine, and the stock rose dramatically. That scenario didn't play out, as ...

Median overall survival, a secondary endpoint, reached nearly 3.5 years with Johnson & Johnson's RYBREVANT® plus LAZCLUZE® in atypical EGFR-mutated disease Consistent ...

A major global study warns mental disorders are now the world’s leading cause of disability, with anxiety and depression ...

Surpass-Early randomized ~800 adults with ≤4-year type 2 diabetes on metformin to add tirzepatide or intensify care, predominantly with semaglutide or dulaglutide comparators. At two years, ...

Dayananda Sagar University (DSU), one of the top higher education institutions in Bengaluru, Karnataka, operates out of three ...

A total of 16.28% of patients with COVID-19 have developed postacute sequelae (PASC), or long-term symptoms that develop weeks or months after an infection. That is according to a May investigation ...

The developers of a “historic” vaccine to save koalas from endemic chlamydia disease have walked away from published findings that it slashed deaths by nearly two thirds, amid accusations they ...

The Federal Reserve Bank of New York wrote that it noticed a ‘remarkable increase in food insecurity, particularly in lower-educated and lower-income households’ ...

If you have a substance that is approved by law, you should be able to make a decision on your health and what you want to do ...

The FDA’s outside vaccine advisers overwhelmingly recommended Thursday that the agency direct manufacturers to base their 2026-2027 formulas on the dominant XFG Covid variant.

FDA panel backs fall Covid shot update to target the XFG variant, enabling manufacturers to reformulate vaccines for the upcoming surge season.